Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.52 |
| ▸ | RAF1 | P04049 | 2/20 | 0.51 |
| ▸ | BRAF | P15056 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4516565 | 0.86 | KMT2A (0.64) | ALDH1A1L3MBTL1TDP1LMNASLC6A2 | |
| SCHEMBL1466483 | 0.84 | CRHBP (0.65) | ALDH1A1L3MBTL1CYP3A4NPSR1CYP2C9 | |
| SCHEMBL3634188 | 0.82 | ALDH1A1 (0.80) | ALDH1A1L3MBTL1CYP3A4NPSR1CYP2C9 | |
| SCHEMBL23812446 | 0.80 | TDP1 (0.60) | ALDH1A1L3MBTL1CYP3A4TDP1TSHR | |
| SCHEMBL17202499 | 0.80 | ALDH1A1 (0.68) | ALDH1A1L3MBTL1CYP3A4NPSR1CYP2C9 | |
| SCHEMBL8128313 | 0.80 | TDP1 (0.60) | ALDH1A1L3MBTL1CYP3A4TDP1TSHR | |
| SCHEMBL16016782 | 0.80 | ALDH1A1 (0.63) | ALDH1A1L3MBTL1CYP3A4NPSR1CYP2C9 | |
| SCHEMBL50441 | 0.79 | ALDH1A1 (0.89) | ALDH1A1L3MBTL1CYP3A4NPSR1CYP2C9 | |
| SCHEMBL29388715 | 0.79 | ALDH1A1 (0.89) | ALDH1A1L3MBTL1CYP3A4NPSR1CYP2C9 | |
| SCHEMBL1466202 | 0.79 | ALDH1A1 (0.57) | ALDH1A1L3MBTL1NPSR1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697737-B2 | Raf modulators and methods of use | EXELIXIS, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110071145-A1 | Raf Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-7846959-B2 | Raf modulators and methods of use | EXELIXIS, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20080009488-A1 | Raf Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-01-10 | — | — | US | disclosed |
| EP-1751124-A2 | RAF MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005112932-A2 | RAF MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009488-A1 | Raf Modulators and Methods of Use | BRAF, RAF1, ARAF | ALDH1A1 2799/4885L3MBTL1 2863/4885CYP3A4 4591/4885 |
| US-20110071145-A1 | Raf Modulators And Methods Of Use | BRAF, RAF1, ARAF | ALDH1A1 2219/4885L3MBTL1 3578/4885CYP3A4 3570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.